Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03297775 · ClinicalTrials.gov registry record

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

A clinical trial of Rheumatoid Arthritis and Interstitial Lung Disease, sponsored by University of Colorado, Denver.

Recruiting
Registry status
750
Enrollment target
1
Study location

NCT03297775 is a study of Rheumatoid Arthritis and Interstitial Lung Disease that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 750 participants, below the 4,687-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03297775, a study of Rheumatoid Arthritis and Interstitial Lung Disease, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
750 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Study Locations (1)

Colorado

  • University of Colorado - Anschutz Medical Campus - Aurora

Trial Details

FieldValue
Enrollment Target 750 participants
Start Date 2017-06-22
Est. Completion 2027-06

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT03297775

The ClinicalTrials.gov registry entry for NCT03297775 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,687-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (84% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT03297775 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT03297775 about?

NCT03297775 is a clinical study titled "Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease". The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g....

What is the current status of trial NCT03297775?

This trial is currently recruiting. The enrollment target is 750 participants. The study started on 2017-06-22. Estimated completion is 2027-06.

What conditions does trial NCT03297775 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Interstitial Lung Disease.

Who is sponsoring clinical trial NCT03297775?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03297775 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.